NASDAQ:AKBA 1 December 2025

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio shares jumped as much as 170% intraday on December 1 after announcing the sale of its Phase 2 drug ADX-097 to Akebia Therapeutics for $12 million upfront and up to $592 million in milestones. Trading volume soared into the hundreds of millions. The company will now focus on its lead autoimmune drug, bempikibart, for alopecia areata.

1 December 2025

Mergers & Acquisitions·NASDAQ:AKBA·NASDAQ:QTTB·Stock Market

York Space Systems Shares Drop Sharply Amid Valuation Concerns but DCF Model Shows Potential Undervaluation
March 20, 2026, 2:27 PM EDT. York Space Systems (YSS) shares have fallen 47.4% year-to-date amid rising concerns over short-term pressure and sector volatility in satellite technology and defense. The stock declined 11.5% over the past week and nearly 37% over 30 days, reflecting shifting market sentiment. Despite the decline, a Discounted Cash Flow (DCF) analysis estimates an intrinsic value of $33.45 per share, significantly above the current price of $17.68, suggesting the shares may be undervalued by 47.2%. The company reported a free cash flow loss of $20.7 million over the last twelve months but projects growth to $255.7 million by 2035. York Space Systems scores low on valuation metrics, indicating potential risks for investors amid uncertainty in funding and contracts within the space sector.